Tampa Bay Company Searching for Other Vaccine Methods

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, is in the pre-clinical phase of developing a vaccine they say would solve two critical problems when it comes to ending the pandemic.

Stuart Raetzman Appointed as Interim CEO at TearClear

UF startup and UF Innovate | Sid Martin Biotech resident client TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.

Everything You Need To Know About Vaccines and COVID-19

Dr. Peter Khoury, president and CEO of UF startup and UF Innovate | Sid Martin Biotech graduate Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), talked with James Di Virgilio, Radio Cade’s host, about vaccinations and COVID-19.

Oragenics Chases Vaccine for Niche Markets

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, seeks to be a major player in the Super Bowl of the pharmaceutical industry: a COVID-19 vaccine.

Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer

UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology.

New OxThera/Oxabact US Patent Granted

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.